We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes.
- Authors
Lin, Y.‐C.; Chen, R.‐Y.; Chen, S.‐W.; Hsieh, T.‐C.; Yen, K.‐Y.; Liang, J.‐A.; Yang, S.‐N.; Wang, Y.‐C.; Chen, Y.‐H.; Chow, N.‐H.; Kao, C.‐H.
- Abstract
Objectives This study correlated immunohistochemical studies with fluorodeoxyglucose ( FDG) uptake on positron emission tomography-computed tomography ( PET- CT) and identified prognostic factors for radiotherapy ( RT)-based treatment outcomes in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Methods Genomic data from pre-treatment biopsy specimens ( Glut1, CAIX, VEGF, HIF-1α, EGFR, Ki-67, Bcl-2, CLAUDIN-4, YAP-1, c-Met and p16) of 76 patients were analysed using tissue microarrays. FDG uptake was evaluated using the maximum standardised uptake value ( SUVmax), metabolic tumour volume ( MTV) and total lesion glycolysis ( TLG). Results The overexpression of Glut1 positively associated with increased values of the SUVmax, MTV and TLG, whereas VEGF and HIF-1α expression with the MTV and TLG, respectively. A VEGF immunoreactive score ( IRS) >2 ( P = 0.001, hazard ratio [ HR] = 3.94) and an MTV defined by an SUV of 2.5 ( MTV2.5) >14.5 mL ( P = 0.004, HR = 3.31) were prognostic factors for low cause-specific survival, whereas a VEGF IRS >2 ( P = 0.02, HR = 2.83) for low primary relapse-free survival. Conclusion The overexpression of Glut1, VEGF and HIF-1α associated with increased FDG uptake. For patients with pharyngeal cancer requiring RT, the treatment outcome can be stratified by VEGF and MTV2.5.
- Subjects
DIAGNOSTIC immunohistochemistry; FLUORODEOXYGLUCOSE F18; GLUCOSE synthesis; POSITRON emission tomography; MEDICAL imaging systems
- Publication
Clinical Otolaryngology, 2017, Vol 42, Issue 3, p608
- ISSN
1749-4478
- Publication type
Article
- DOI
10.1111/coa.12783